Abstract: An aqueous polymer dispersion prepared by free-radical polymerization of vinyl acetate in the presence of at least one ionic emulsifier, at least one free-radical initiator and at least one protective colloid, wherein the polymerization is carried out in the presence of a polymerization regulator and wherein the ratio by weight of protective colloid to ionic emulsifier is at least 4:1 and wherein the ratio by weight of vinyl acetate monomer to protective colloid is between 19:1 and 4:1.

Abstract: The present invention relates to water-soluble or water-dispersible copolymers obtainable by free-radical polymerization of a) 80 to 20% by weight of hydroxy-C1–C6-alkyl (meth)acrylate and, where appropriate, one or more compounds of the formula (A) or (B) with R1=H, C1–C6-alkyl, R2=H, CH3 R3=C1–C24-alkyl or mixtures thereof in the presence of b) 20 to 80% by weight of polyvinyl alcohol (PVA) and c) where appropriate 0 to 20% by weight of other polymerizable compounds (C), a process for their preparation, and their use as coating agent, binder and/or film-forming excipient in pharmaceutical dosage forms.

Abstract: A solid oral pharmaceutical dosage form of a sympathomimetic with impeded extractability of the sympathomimetic, comprising I) a sympathomimetic (component I) II) an excipient mixture (component II) composed of a) 5 to 50% by weight of hydroxyalkylcelluloses or alkylcelluloses or mixtures thereof b) 5 to 70% by weight of xanthan c) 5 to 50% by weight of an alkaline earth metal salt of a C10-C30 fatty acid d) 10 to 70% by weight of an alkali metal or alkaline earth metal salt of a mineral acid, of a sulfonic acid or of a C2-C6 carboxylic acid or mixtures thereof, where the total of components a) to d) is 100% by weight, where the ratio of active ingredient to excipient mixture II) is from 1:2 to 3:1 by weight.

Abstract: Described are a method of killing microorganisms in aqueous industrial systems or products for industrial applications based on water by adding from 0.001 to 5% by weight of a water-soluble or water-dispersible polymer containing from 30 to 100 mol % of styrenesulfonic acid, from 0 to 40 mol % of an N-vinyllactam and/or N-vinylamine, and from 0 to 30 mol % of further free-radically polymerizable monomers as biocidal additive, and a method of protecting articles by applying an antimicrobial aqueous composition comprising such an additive.

Abstract: An aqueous polymer dispersion for use as binder and coating agent for pharmaceutical dosage forms, obtained by free-radical polymerization in an aqueous system in the presence of a polymerization initiator of i) 60 to 99.95% by weight of at least one monomer selected from the group consisting of alkyl acrylates, alkyl methacrylates and vinyl esters of C1-C24 carboxylic acids, ii) 0.05 to 5% by weight of a monoolefinically unsaturated C3-C8 carboxylic acid iii) 0 to 35% by weight of further free-radical polymerizable monomers, where the total of i), ii), and iii) equals 100% by weight, in the presence of 0.001 to 1.0% by weight, based on the total weight of the monomers, of an anionic emulsifier.

Abstract: A quick dissolving film coating composition for coating solid substrates is composed of a) 10-90% by weight of a polyvinyl alcohol-polyether graft copolymer (component A), b) 5-80% by weight of at least one further component containing at least one functional group selected from the group consisting of hydroxyl, amide and ester functions (component B), and c) 0-70% by weight of further customary coating constituents (components C).

Abstract: The invention relates to the combination of polyvinyl acetate and water-insoluble, acid-insoluble, or alkali-insoluble polymers used for producing film coatings for forms of administration in which agents are released in a controlled manner, and methods for the production thereof. The controlled-release properties can be specifically adjusted by means of said combinations, resulting in films having excellent mechanical stability and storage stability. In particular, agents are released independent of the pH by means of the inventive forms of administration.

Abstract: The present invention relates to hard capsules comprising (A) polymers obtainable by free-radical polymerization of a) at least one vinyl ester in the presence of b) polyether-containing compounds and c) where appropriate one or more other copolymerizable monomers c) and subsequent at least partial hydrolysis of the ester functions in the original monomers a), with the proviso that in the absence of another copolymerizable monomer c) the polyether-containing compound b) must have a number average molecular weight ≦10,000, (B) where appropriate structure-improving auxiliaries and (C) other conventional shell constituents, the production and use thereof.

Abstract: The present invention relates to soft capsules comprising (a) polymers prepared by polymerization of vinyl esters in the presence of polyethers (b) where appropriate structure-improving auxiliaries and (c) where appropriate other conventional constituents, the use and production thereof.

Abstract: The description is given of the use of particulate water-insoluble polymer preparations comprising at least one polymer P that is essentially made up of hydrophilic polymer segments and hydrophobic polymer segments as filter aids for filtering aqueous liquids.

Abstract: A process for preparing aqueous polymer dispersions by means of a polymerization, conducted in an aqueous system, of at least one free-radically polymerisable ethylenically unsaturated monomer in the presence of a polymerisation initiator, wherein the pH of the aqueous dispersion is adjusted during the preparation process by adding at least two different, basic reagents, at least one of said basic reagents being added in a plurality of stages.

Abstract: Use of water-soluble of water-dispersible, film-forming graft polymers obtainable by free-radical polymerization of

Abstract: The present invention relates to oral dosage forms comprising a) one or more active ingredients b) a formulated mixture of polyvinyl acetate and polyvinylpyrrolidone c) where appropriate other excipients customary for producing the dosage form, wherein they float on gastric fluid and display delayed release of active ingredient, and to the use and production thereof.

Abstract: An aqueous polymer dispersion prepared by free-radical polymerization of vinyl acetate in the presence of at least one ionic emulsifier, at least one free-radical initiator and at least one protective colloid, wherein the polymerization is carried out in the presence of a polymerization regulator and wherein the ratio by weight of protective colloid to ionic emulsifier is at least 4:1 and wherein the ratio by weight of vinyl acetate monomer to protective colloid is between 19:1 and 4:1.

Abstract: The present invention relates to pharmaceutical single-unit administration forms provided with a sealed film coating and having delayed release, the film coating containing 30 to 100% by weight of polyvinyl acetate and the layer thickness of the film coating being 30 &mgr;m to 500 &mgr;m.

Abstract: The use of polymers which are obtainable by polymerization of a) at least one vinyl ester of aliphatic C1-C24-carboxylic acids in the presence of b) polyethers of the general formula I,  in which the variables have, independently of one another, the meanings mentioned in the description, as coating agent, binder and/or film-forming excipient in pharmaceutical presentations.

Abstract: (Meth)acrylic acid copolymers are used to increase mucosal permeability, comonomers present being (meth)acrylic esters and/or other monomers capable of free-radical polymerization, and the (meth)acrylic acid:comonomer molar ratio varying from 99:1 to 1:99.

Abstract: The present invention relates to the use of 5′-deoxy-5′-methylthioadenosine in skin cosmetic compositions for improving the appearance of the skin, to such compositions and to a method for the cosmetic treatment of the skin.

Abstract: The present invention relates to oral dosage forms comprising

Abstract: The invention relates to the use of copolymers comprising a) 82 to 99.9 mol % of at least one monoethylenically unsaturated C3-C8-carboxylic acid; b) 0.1 to 18 mol % of at least one monomer selected from the group b1) N—C8-C30-alkyl-substituted amides of monoethylenically unsaturated C3-C8-carboxylic acids, b2) N,N—C8-C30-dialkyl-substituted amides of monoethylenically unsaturated C3-C8-carboxylic acids, b3) C8-C30-alkyl esters of monoethylenically unsaturated C3-C8-carboxylic acids; c) 0 to 17.9 mol % of at least one monomer selected from the group of c1) vinyl esters of aliphatic C8-C30-carboxylic acids, c2) C8-C30-alkylvinyl ethers, the mol % data for the individual components adding up to 100%, as solubilizer.